Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD

Alzheimer Disease Clinical Trial

— IL-2-AD  

Official title:

Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05468073
• Other study ID #: D20-P012
• Status: Recruiting
• Phase: Phase 2
• Start date: October 11, 2022
• Est. completion date: September 1, 2026

Study information

• Verified date: June 2024
• Source: Centre Hospitalier St Anne
• Contact: Khaoussou SYLLA, Dr
• Phone: 01 45 65 76 78
• Email: k.sylla[@]ghu-paris.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study aims at evaluating the therapeutic efficacy and safety of low-dose IL-2 immunomodulatory treatment in patients with early AD, in a phase II, randomized, double blind, placebo-controlled phase II clinical trial. Patients with AD at early stage will be recruited and randomized (2:1) in each treatment group. The primary endpoint is the rate of decline assessed through CDR change at 18 months between the placebo group and the treated patients.

Description:

This study aims to investigate the immunomodulatory therapeutic potential and safety of low-dose (ld) IL-2 in a randomized, double blind, and placebo-controlled phase II clinical trial. Conservative diagnosis criteria based on clinical and CSF biomarkers have been established to avoid risks of misdiagnosis. The treatment consist of 21 cures of subcutaneous injections of either placebo or low-dose (1MIU/day) IL-2 (PROLEUKIN ®). Patients will receive 5 consecutive injections during the induction phase which will be followed by a week break. During the maintenance phase a total of 16 injections will be administered weekly. Total duration of treatment for each patient is anticipated to be 18 weeks. Patients will be followed-up for 18 months after the first injection. At inclusion, in addition to the clinical evaluation, a hybrid PET/MRI (using [18F]-DPA-714) scan will be performed. After randomized patients successfully complete the treatment phases, they will be followed-up through 3 clinical and 1 neuroimaging visits to assess cogitive and functional decline. Clinical visits are scheduled at 6, 12, and 18 months after treatment induction. Another hybrid PET/MRI (using [18F]-DPA-714) scan will be performed at 19 months following induction.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 45
• Est. completion date: September 1, 2026
• Est. primary completion date: September 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients aged > 18
• Age of disease onset < 70 years
• Clinical and biological diagnosis of AD based on
• Progressive amnestic syndrome associated or not with other cognitive impairments
• Biological criteria: CSF biomarkers suggestive of AD.
• Brain MRI congruent with the diagnosis, left to the appreciation of the investigator
• CDR (Clinical Dementia Rating Scale) = 0.5 or 1
• If patients have an antidepressant or acetylcholinesterase inhibitors treatment, patients must be treated with stable doses of treatment for at least 1 month before inclusion.
• Have a caregiver who provides a separate written informed consent to participate. If a caregiver/study informant cannot continue, one replacement is allowed.
• Have adequate vision and hearing for neuropsychological testing in the opinion of the investigator.
• Have given written informed consent approved by the ethical review board (ERB) governing the site.
• The patient has to have a French social security number and be fluent and literate in French.

Exclusion Criteria:

• Subject with a psychiatric evolutionary and/or badly checked.
• Subject with a grave, severe or unstable pathology (left to the judgement of the investigator) the nature of which can interfere with the variables of evaluation.
• Epileptic subjects
• Subject under guardianship or curatorship
• Subject presenting contraindications to the MRI
• Known or supposed history (< or = 5 years) of severe alcoholism or misuse of drugs
• Vascular, inflammatory or expansive, visible lesion in the MRI, which can interfere on the criteria of diagnosis.
• No health insurance
• Women of childbearing potential: a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
• History of auto-immune disease
• History within the past 10 years of a primary or recurrent malignant disease
• Diagnosis or history of other possible etiology of dementia, including but not limited to other neurodegenerative disorders (FTD, LBD, VaD, HD, PD, PSP-CBD).
• Renal dysfunction at inclusion, clearance <30 mL/min
• Chronic hepatic diseases as indicated by liver function tests abnormalities
• Abnormal thyroid function
• Therapeutic trial within 1 year preceding the first study period, or participation in a trial with active or passive immunization against amyloid if patient was assigned to the active treatment arm.
• Clinically significant evidence of Active viral infection (CMV, EBV, HCV, HBV, TPHA-VDRL, HIV)
• Current or medical history of severe cardiopathy,
• - Severe dysfunction in a vital organ
• Patients with White Blood Count (WBC) < 4.000/mm3; platelets < 100.000/mm3; hematocrit (HCT) < 30%.
• Patients with serum bilirubin and creatinine outside normal range.
• Patients with organ allografts.
• Patients who are likely to require corticosteroids

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Drug:
• Proleukin
Sub-cutaneous injections of Interleukin-2 (PROLEUKIN ®) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks
• Placebo
Sub-cutaneous injections of placebo (NaCl) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks.

Locations

Country	Name	City	State
France	GHU Saint Anne	Paris

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier St Anne	For Drug Consulting

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline CDR score at 18 months	The primary endpoint will be evaluated in all patients evaluable for efficacy, i.e. patients who received at least one cure of IL-2 and were evaluated for cognitive and functional status at baseline and 18 months.; The response variable will be dichotomized as follows: Responder patient = 1 (end of study CDR score <= baseline CDR score); Non-responder patient = 0 (end of study CDR score > baseline CDR score)	18 months
Secondary	Rate of cognitive decline between placebo and treatment groups as assessed by changes in MMSE scores at baseline, 6, 12, and 18 months	MMSE total score out of 30	6, 12 and 18 months
Secondary	Rate of cognitive decline between placebo and treatment groups as assessed by changes in ADAS-Cog 13 items scores at baseline, 6, 12, and 18 months	ADAS-Cog total score out of 85	6, 12 and 18 months
Secondary	Rate of functional decline between placebo and treatment groups as assessed by changes in ADCS-ADL MCI scores at baseline, 6, 12, and 18 months	ADSC-ADL MCI total score out of 53	6, 12 and 18 months
Secondary	Rate of functional decline between placebo and treatment groups as assessed by changes in CDR (sum of boxes) scores at baseline, 6, 12, and 18 months	CDR sum of the boxes (CDR-SOB) total score out of 18	6, 12 and 18 months
Secondary	Change in neuroimmune reaction as assessed by [18F]-DPA-714 PET global cortical index and regional cortical binding at baseline and 18 months between placebo and treated groups	Global and regional cortical [18F]-DPA-714 PET uptake ratio	18 months
Secondary	Change in peripheral frequency of Treg and other immune effectors at 18 months compared to baseline between placebo and treated groups	Tregs frequency, total lymphocytes as a biomarker of target engagement	6, 12 and 18 month
Secondary	Change in hippocampal atrophy at 18 month compared to baseline between placebo and treated groups	Volume of hippocampus measured in T1 MRI	18 months
Secondary	Number of patients with treatment related adverse events as assessed by clinical safety panel	Clinical safety will be assessed via the following assessments: Vital signs (including blood pressure, weight, BPM, temperature) - each visit; ECG - at inclusion and at V22 (M18); Check-list questionnaire to assess clinical adverse events - each visit	18 months
Secondary	Number of patients with treatment related adverse events as assessed by blood laboratory safety panel	Biological safety will be evaluated and controlled through blood laboratory safety tests which include the following: Thyroid function: T4 and TSH - at inclusion, at V21; Haematology (RBC, WBC, leukocyte formula, platelets) and C reactive protein (CRP) - at inclusion, 8 days before the randomization, each day of the induction phase (day 1 to day 5), before each injection of the maintenance phase until V7, then every fortnight until the last injection of the maintenance phase, and then at M6, M12 and M18.; Biochemistry (electrolytes, proteins, albumin, urea, creatinine, glucose, AST, ALT, GGT, bilirubin) and Coagulation tests - at inclusion, 8 days before the randomization, every 2 months for 6 months (V9 and V17), and at M6, M12 and M18	18 months